Evidence map›Paper›PMID 20591162›Full record

ArticleJournal of medical case reports2010

Small cell neuroendocrine tumor of the breast in a 40 year-old woman: a case report.

Stefania Nicoletti, Maximilian Papi, Fabrizio Drudi, Manuela Fantini, Debora Canuti, Emiliano Tamburini, Cinzia Possenti, Enzo Pasquini, Massimo Brisigotti, Alberto Ravaioli

Open access · goldAbstract read
In one paragraph

Article in Journal of medical case reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  5. Neuroendocrine breast carcinoma: a rare but challenging entity.Medical oncology (Northwood, London, England) · 2020
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Stefania NicolettiOncology and Oncoematology Department, 'Infermi' Hospital, Via Settembrini 2, Rimini, 47921 Italy. aravaiol@auslrn.net.
Maximilian Papi
Fabrizio Drudi
Manuela Fantini
Debora Canuti
Emiliano Tamburini
Cinzia Possenti
Enzo Pasquini
Massimo Brisigotti
Alberto Ravaioli
Ospedale Infermi di Rimini · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale Cervesi di Cattolica · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSmall cell neuroendocrine cancer of the breast is a rare tumor with less than 30 cases reported in the literature. The morphological and immunohistochemical patterns of this tumor are similar to small cell neuroendocrine cancer of the lung. For this reason, it is often difficult to distinguish a primary small cell neuroendocrine cancer of the breast from a metastatic lesion from other sites. CASE PRESENTATION: We report and characterize with immunohistochemical techniques a case of primary small cell neuroendocrine cancer of the breast occurring in a 40-year-old Caucasian woman. A palpable and mobile 3.0 cm tumor was located in the upper-outer quadrant of her right breast. Lumpectomy and subsequent radical mastectomy with axillary lymph node resection were performed. Microscopically, the tumor consisted predominantly of a diffuse proliferation of small oat cells. The tumor cells were positive for neuroendocrine markers chromogranin A and synaptophysin. One of 16 lymph nodes was metastatic. A correct treatment needs to be chosen.

conclusionsIt has recently been demonstrated that early small cell neuroendocrine cancer of the breast shows a good prognosis with adjuvant treatments with high disease free survival. Our patient is alive and well without disease eight years after treatment. We performed an adjuvant therapy with the classic scheme doxorubicin and cyclophosphamide, followed by carboplatin and etoposide. A more extensive review is required to define a standard treatment protocol for this rare neoplasm.

Identifiers

PMID20591162
PMCPMC2913980
OpenAlexW2059037899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.